21st.Bio files EU novel food application for precision fermented whey protein
21st.Bio has filed an EU novel food application for BLG Essential+, its precision fermented beta-lactoglobulin, and wants a fast-track route in Europe.
21st.Bio has filed an EU novel food application for BLG Essential+, its precision fermented beta-lactoglobulin, Green Queen reported on 13 November 2026. The dossier went to the European Commission for safety assessment by the European Food Safety Authority. The company is based in Copenhagen, was founded in 2020 by Thomas G Schmidt and Per Falholt, and runs laboratories in Copenhagen and in Davis, California.
Beta-lactoglobulin is the main protein in dairy whey. 21st.Bio produces it in Aspergillus oryzae, the koji mould, on a platform Novonesis developed over decades, and it licenses part of that technology from Novonesis, which is owned by Novo Holdings. Novo Holdings invested 86 million euros in 2021 for an ownership share. A peer reviewed paper published last year in Applied Microbiology and Biotechnology described the strain lineage as the first mycotoxin-free Aspergillus oryzae lineage for industrial production of alternative and novel proteins, with the penicillin G gene cluster inactivated. “This is a well-characterized production platform with consumer safety designed into the strain,” said José Arnau, the company's chief of strain engineering and regulatory affairs.
The United States route is already clear. 21st.Bio self-affirmed GRAS status in September 2024 and received a no-questions letter from the Food and Drug Administration on its GRAS notice in October 2025, according to Nutrition Insight. No precision fermented beta-lactoglobulin has been authorised in the European Union. Perfect Day, Remilk, Imagindairy, Vivici and Verley have all cleared the US route, per Green Queen, which leaves Europe behind on a protein class that is already approved for sale in America.
Alongside the filing the company asked European regulators for a fast-track route for nature-identical food proteins made in host strains with a demonstrated record of safe use, arguing that this would hold EU safety standards while giving applicants a clearer timetable. 21st.Bio says preparing the dossier took years and significant investment, and that the uncertain approval timeline makes investment planning difficult. “This is not a choice between safety and speed,” said Thomas G Schmidt, co-founder and chief executive, who added that “Europe has the science, the companies, and the industrial heritage in precision fermentation.” Green Queen puts beta-lactoglobulin at 65 per cent of dairy whey content and 45 per cent higher in leucine than commercially available whey protein isolates, and cites a Rabobank projection that global dairy output will fall 31 million tonnes short of demand in milk equivalents by the end of the decade.
Why it matters for AgTech founders: this is a timetable problem wearing the clothes of a science problem. The asset that carries value here is not the protein, which is nature-identical and therefore not patentable as a molecule. It is the regulatory file plus a production strain with documented safe use, which is exactly why 21st.Bio licenses the Aspergillus oryzae platform instead of inventing a host. Anyone building on a novel organism should expect to fund that safety history themselves, and should budget it as a capital item rather than a compliance line. Two further points travel into other categories. One, clear the United States first and file in Europe second is now the default sequence, and it quietly moves first revenue, first plant and first reference customer out of Europe. Two, an approval date nobody can name is priced into every European term sheet whether or not it appears in the deck, so founders raising on a European manufacturing story should model the gap explicitly instead of assuming Brussels closes it.
21st.Bio files EU novel food application for precision fermented whey protein
The Copenhagen company has put BLG Essential+ in front of EFSA and is asking Brussels for a faster route for proteins whose production strains already carry a safety record.
21st.Bio has filed an EU novel food application for BLG Essential+, its precision fermented beta-lactoglobulin, Green Queen reported on 13 November 2026. The dossier went to the European Commission for safety assessment by the European Food Safety Authority. The company is based in Copenhagen, was founded in 2020 by Thomas G Schmidt and Per Falholt, and runs laboratories in Copenhagen and in Davis, California.
Beta-lactoglobulin is the main protein in dairy whey. 21st.Bio produces it in Aspergillus oryzae, the koji mould, on a platform Novonesis developed over decades, and it licenses part of that technology from Novonesis, which is owned by Novo Holdings. Novo Holdings invested 86 million euros in 2021 for an ownership share. A peer reviewed paper published last year in Applied Microbiology and Biotechnology described the strain lineage as the first mycotoxin-free Aspergillus oryzae lineage for industrial production of alternative and novel proteins, with the penicillin G gene cluster inactivated. “This is a well-characterized production platform with consumer safety designed into the strain,” said José Arnau, the company's chief of strain engineering and regulatory affairs.
The United States route is already clear. 21st.Bio self-affirmed GRAS status in September 2024 and received a no-questions letter from the Food and Drug Administration on its GRAS notice in October 2025, according to Nutrition Insight. No precision fermented beta-lactoglobulin has been authorised in the European Union. Perfect Day, Remilk, Imagindairy, Vivici and Verley have all cleared the US route, per Green Queen, which leaves Europe behind on a protein class that is already approved for sale in America.
Alongside the filing the company asked European regulators for a fast-track route for nature-identical food proteins made in host strains with a demonstrated record of safe use, arguing that this would hold EU safety standards while giving applicants a clearer timetable. 21st.Bio says preparing the dossier took years and significant investment, and that the uncertain approval timeline makes investment planning difficult. “This is not a choice between safety and speed,” said Thomas G Schmidt, co-founder and chief executive, who added that “Europe has the science, the companies, and the industrial heritage in precision fermentation.” Green Queen puts beta-lactoglobulin at 65 per cent of dairy whey content and 45 per cent higher in leucine than commercially available whey protein isolates, and cites a Rabobank projection that global dairy output will fall 31 million tonnes short of demand in milk equivalents by the end of the decade.
Why it matters for AgTech founders: this is a timetable problem wearing the clothes of a science problem. The asset that carries value here is not the protein, which is nature-identical and therefore not patentable as a molecule. It is the regulatory file plus a production strain with documented safe use, which is exactly why 21st.Bio licenses the Aspergillus oryzae platform instead of inventing a host. Anyone building on a novel organism should expect to fund that safety history themselves, and should budget it as a capital item rather than a compliance line. Two further points travel into other categories. One, clear the United States first and file in Europe second is now the default sequence, and it quietly moves first revenue, first plant and first reference customer out of Europe. Two, an approval date nobody can name is priced into every European term sheet whether or not it appears in the deck, so founders raising on a European manufacturing story should model the gap explicitly instead of assuming Brussels closes it.